# BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

> **NCT02672852** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 507 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02672852
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-29
- **Primary completion:** 2017-08-02
- **Final completion:** 2018-07-26
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2019-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02672852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02672852, "BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02672852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*